Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof
Specific binding members, featuring certain residues of the third CDR of the antibody NH576 (portions of SEQ ID NO:2) are provided, together with their use in methods of treatment and diagnosis.
1. An isolated antibody comprising a heavy chain variable domain comprising an amino acid sequence as set forth as residues 31-36, 51-66 and 99 to 106 of SEQ ID NO: 2; and further comprising a light chain variable domain comprising an amino acid sequence as set forth as residues 23-33, 49-55 and 88 to 98 of SEQ ID NO: 4.
2. An isolated antibody according to claim 1 , wherein said amino acid sequences are carried by a human antibody framework.
3. An isolated antibody according to claim 1 , comprising the polypeptide sequence of SEQ ID NO: 2.
4. An isolated antibody according to claim 1 , comprising the polypeptide sequence as set forth in SEQ ID NO: 4.
5. An isolated antibody according to claim 4 wherein said amino acid sequences are carried by a human antibody framework.
6. An isolated antibody according to claim 5 in the form of an antibody F(ab′)2 or scFv fragment.
7. An isolated antibody according to claim 1 , wherein said antibody carries a label.
8. An isolated antibody according to claim 7 , wherein the label is selected from the group consisting of a detectable label and a functional label.
9. An isolated antibody according to claim 8 , wherein said detectable label is selected from the group consisting of radiolabels, enzyme labels, chemical moieties bound to a specific cognate detectable moiety.
10. An isolated antibody according to claim 9 , wherein at least one of the following is true: said radiolabel is selected from the group consisting of 131 I and 99 Tc, said enzyme label is horseradish peroxidase, said chemical moieties bound to a specific cognate detectable moiety label is labeled avidin, said functional label is selected from the group consisting of toxins and enzymes capable of converting prodrugs into active drugs, said functional label is ricin, said functional label is carboxypeptidase and said functional label is nitroreductase.
11. An isolated antibody according to claim 1 , wherein said antibody is fused to an additional polypeptide.
12. An isolated antibody according to claim 11 , wherein said additional polypeptide is joined to the C-terminal or N-terminal end of said specific binding member.
13. An isolated antibody according to claim 11 , wherein said additional polypeptide is joined to said specific binding member by a polypeptide linker.
14. An isolated antibody according to claim 11 , wherein said additional polypeptide is designed to be targeted to the site of a tumor.
15. An isolated antibody according to claim 1 , wherein said antibody is fused to an additional polypeptide.
16. An isolated antibody according to claim 15 , wherein said additional polypeptide is joined to the C-terminal or N-terminal end of said antibody.
17. An isolated antibody according to claim 15 , wherein said additional polypeptide is joined to said antibody by a polypeptide linker.
18. An isolated antibody according to claim 15 , wherein said additional polypeptide is designed to be targeted to the site of a tumor.